Brief survey of Cleveland BioLabs Inc. (NASDAQ:CBLI)


Cleveland BioLabs, Inc. (NASDAQ:CBLI) has released results for the last fiscal year, reporting EPS of $-0.33.  For this year, EPS is expected to grow 86.50% over the previous year.

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend. The market is approaching overbought territory. Be watchful of a trend reversal.

Recently, Cleveland BioLabs, Inc. (NASDAQ:CBLI) reported financial results and development progress for the first quarter ended March 31, 2017.

For the last five years, EPS at Cleveland BioLabs, Inc. has increased 37.10%, while rise sales have increased -16.70%% over the same period. Tthe combined EPS growth for the next five years is expected to be -%.

Shares of Cleveland BioLabs, Inc. are now trading at $4.14, giving it market capitalization of $45.62M. Over the last 12 months, shares of Cleveland BioLabs, Inc. have risen to maximum of $-25.41% and dropped to a minimum of $239.34%.

The stock?s beta, which is a measure of volatility, is 0.38. For the sake of clarifty, keep in mind that a bet of less than 1 indicates that a stock is less volatile compared to the overall market, while a beta greater than 1 implies a stock is more volatile than the market.

Cleveland BioLabs, Inc. has 20-Day Simple Moving Average of $23.25% and 50-Day Simple Moving Average of $58.60%. The 200-Day Simple Moving Average is $114.03%.

The stock’s weekly performance stands at 21.05%% while its monthly performance is 5.07%. Year-to-date the stock has moved 191.54% compared to a performance of 100.00%% over the last 12 months.

Cleveland BioLabs, Inc. has witnessed 0.00% insider transactions, leading to insider ownership of 3.83%. That compares to 2.40% ownership by institutional investors following -7.03% institutional transactions.

Return on investments in Cleveland BioLabs, Inc. for the trailing 12 months is -84.70%, while return on assets for the same period is -22.50%. Return on equity for the trailing 12 months, on the other hand, is -48.50%.

Cleveland BioLabs, Inc. has RSI (Relative Strength Index) of 64.98.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.